Iqvia Holdings Inc (NYSE:IQV) – Equities research analysts at William Blair increased their Q1 2018 earnings per share estimates for Iqvia in a research note issued to investors on Thursday. William Blair analyst J. Kreger now forecasts that the medical research company will earn $1.24 per share for the quarter, up from their prior estimate of $1.19. William Blair also issued estimates for Iqvia’s Q2 2018 earnings at $1.32 EPS and FY2020 earnings at $7.26 EPS.
Iqvia (NYSE:IQV) last posted its quarterly earnings results on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, topping the Zacks’ consensus estimate of $1.14 by $0.05. Iqvia had a return on equity of 12.60% and a net margin of 0.58%. The company had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.01 billion. During the same period in the previous year, the firm earned $1.00 EPS. The firm’s revenue was up 77.6% compared to the same quarter last year.
Iqvia (NYSE:IQV) opened at $100.04 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 1.29. Iqvia has a twelve month low of $74.80 and a twelve month high of $110.67. The company has a market capitalization of $20,810.00, a P/E ratio of 344.97, a P/E/G ratio of 1.38 and a beta of 0.61.
In other news, insider James H. Erlinger III sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 20th. The stock was sold at an average price of $101.21, for a total transaction of $1,012,100.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total value of $764,776,314.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,806,558 shares of company stock worth $898,722,108. Corporate insiders own 6.40% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC bought a new position in shares of Iqvia during the 4th quarter valued at approximately $920,000. First Citizens Bank & Trust Co. bought a new position in shares of Iqvia during the 4th quarter valued at approximately $1,067,000. Bremer Trust National Association bought a new position in shares of Iqvia during the 4th quarter valued at approximately $1,445,000. Exxonmobil Investment Management Inc. TX bought a new position in shares of Iqvia during the 4th quarter valued at approximately $2,266,000. Finally, Sheets Smith Wealth Management bought a new position in shares of Iqvia during the 4th quarter valued at approximately $5,770,000. 95.78% of the stock is currently owned by hedge funds and other institutional investors.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.